Welcome to our ninth annual report on US securities class actions filed against publicly traded life sciences companies, which include pharmaceutical, biotechnology, medical device, and healthcare companies....more
3/31/2025
/ Biotechnology ,
Class Action ,
Clinical Trials ,
FDA Approval ,
Health Care Providers ,
Insider Trading ,
Life Sciences ,
Medical Devices ,
Medicare ,
Motion to Dismiss ,
Pharmaceutical Industry ,
Publicly-Traded Companies ,
Scienter ,
Securities and Exchange Commission (SEC) ,
Securities Exchange Act of 1934 ,
Securities Fraud ,
Securities Litigation
We are proud to present our seventh annual Securities Litigation Year in Review publication, in which we analyze data for securities class actions filed nationally against publicly traded pharmaceutical, biotechnology,...more
Summary of 2021 Trends, Themes, and Takeaways -
We are proud to present our sixth annual Securities Litigation Year in Review publication, in which we analyze data for securities class actions filed nationally against...more
In many ways, 2020 was an unprecedented year. In midMarch, the United States abruptly went into lockdown as coronavirus cases began to spike; a national emergency was declared, travel bans and gathering restrictions were...more
4/28/2021
/ Class Action ,
Data Breach ,
Dismissals ,
Duty to Disclose ,
Failure To Disclose ,
False Statements ,
Initial Public Offering (IPO) ,
Investors ,
Misleading Statements ,
Omissions ,
Popular ,
Publicly-Traded Companies ,
Securities and Exchange Commission (SEC) ,
Securities Exchange Act ,
Securities Fraud ,
Securities Litigation ,
Securities Violations ,
Shareholder Litigation ,
Stock Prices